knowledge -WSS

knowledge

author：explore 2025-09-05 06:55:45 - browse：3

A crowd of miniature figurines facing towards an hourglass. -- cancer coverage from STAT — Adobe

It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.

There’s been a proliferation of various biological aging clocks, mathematical models that look at things like genetic markers or proteins in your body to make some estimation of an individual’s biological age. Research interest in using these clocks has exploded. In the last five years, thousands of papers on or incorporating the clocks have been published. The paper describing one popular biological aging clock, PhenoAge, has over 1,800 citations alone. One recent study suggested that a reason cancer incidence is increasing among younger adults may be accelerated aging, based on this particular clock.

But as scientists use these clocks to associate biological age with specific health risks, like cancer or dementia, and numerous companies eagerly offer biological age measurements in exchange for hundreds of bucks, it may be worth noting that experts don’t agree on what “biological age” actually is.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

explore

WSS

Weighted lottery helped low

A new House health package & hospitals’ new site

What drug price negotiations mean for Medicare Part D

NIH nominee Bertagnolli will get October confirmation hearing

Amazon on where the company's health care bets are headed next

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Heart attack and stroke risk calculators need revising

Cord blood banking comes at a high cost to babies

Guidelines to prevent youth baseball injuries need more muscle

Weighted lottery helped low

Virginia high school admissions case could be legal follow

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Alkermes shareholders re

Advances in CAR

Trump demands the U.S. pay no more for drugs than other countries … again

Ionis drug prevents swelling attacks due to hereditary angioedema

entertainment

Woman returns to dialysis after doctors remove transplanted pig kidney

AstraZeneca chief proposes a novel edit to the drug pricing bill

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

knowledge

hotspot

focus

hotspot